Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age
Conditions
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Locations
36
United States
Investigational Site
Birmingham, Alabama, United States
Investigational Site
Dothan, Alabama, United States
Investigational Site
Tucson, Arizona, United States
Investigational Site
Jonesboro, Arkansas, United States
Investigational Site
Anaheim, California, United States
Investigational Site
Downey, California, United States
Start Date
February 17, 2017
Primary Completion Date
October 10, 2017
Completion Date
October 10, 2017
Last Updated
March 28, 2022
NCT07409220
NCT07203755
NCT05590455
NCT05383742
NCT05777499
NCT02979951
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions